Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Invested Capital (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Invested Capital for 2 consecutive years, with $35.3 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 100.44% to $35.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.3 million through Dec 2025, up 100.44% year-over-year, with the annual reading at $35.3 million for FY2025, 100.44% up from the prior year.
  • Invested Capital hit $35.3 million in Q4 2025 for Xilio Therapeutics, up from -$8.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $35.3 million in Q4 2025 to a low of -$8.1 million in Q3 2025.